Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Somatostatin analogs (SSAs) are used to treat acromegaly and neuroendocrine tumors (NETs). Two first-generation SSAs, octreotide and lanreotide, are available to patients (pts).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Cella D
Authors: Feuilly M, Jenni E, Cella D,
Keywords: neuroendocrine tumors, acromegaly, preference, patient reported outcomes,
Introduction: A new lanreotide autogel/depot (LAN) syringe was developed based on feedback from a human factors study to improve user experience.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Truong Thanh X, Adelman D, Feuilly M, Houchard A, Cella D,
Keywords: Somatuline lanreotide, syringe, neuroendocrine tumors, medical treatment,
#2296 First Patient Survey about Tumor - Associated Fatigue in NEN
Introduction: Tumor-associated fatigue (TrF) is a debilitating condition occurring during the course of the tumor disease, and even ongoing after all tumor specific therapies are completed. The syndrome consists of chronic fatigue, sleep disturbances, severe pain, brain-fog and is underestimated by both, patients and doctors. Diagnosis is made according to the criteria by Cella (Cella 2001), although it is felt not to be sufficient.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Germany P
Authors: Banz S, Mellar K, Letsch A, Scheibenbogen C, Pavel M,
Keywords: Tumor related fatigue, online survey, support group, Quality of Life, ability of work,
Introduction: Target therapy has improved the outcome of neuroendocrine tumors (NETs), but little is known about the strategies to overcome the acquired resistance. MET is considered one of the putative mechanisms of resistance. RET is also rearranged in some other endocrine tumors (like thyroid).
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Cella C, Barberis M, Spad F, Pisa E, Laffi A,
Keywords: Everolimus, MET, RET,
Introduction: TELESTAR previously demonstrated the efficacy and safety of TE in pts with CS experiencing >4 Bowel Movements (BM) per day despite stable-dose somatostatin analog therapy. Significantly higher rates of Durable Response (DR, predefined as Bowel Movement (BM) frequency reduction ≥30% from baseline for ≥50% of the 12 week double blind period) were observed with TE (TE 250mg: 44%, TE 500mg: 42%) vs placebo (20%).
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Cella D
Authors: Cella D, Beaumont J, Hudgens S, Marteau F, Feuilly M,
Keywords: telotristat ethyl, HRQoL, carcinoid syndrome,